Katharine Lewis

University of Western Australia

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (9)

Matthew Maurer

Assistant Professor of Biostatistics and Medicine

Mayo Clinic Rochester

UNITED STATES

View details

Chan Yoon Cheah

University of Western Australia

AUSTRALIA

View details

Graham McIlroy

NIHR Academic Clinical Lecturer in Haematology

University of Birmingham

UNITED KINGDOM

View details

Michael Buege

University of Illinois Chicago College of Pharmacy

UNITED STATES

View details

Stephen Opat

AUSTRALIA

View details

Matthew Ku

University of Melbourne

AUSTRALIA

View details

Eliza Hawkes

Associate Professor

MONASH UNIVERSITY

AUSTRALIA

View details

David Bond

Associate Professor

Ohio State University

UNITED STATES

View details

Matthew Wilson

University of Glasgow

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Katharine Lewis

Research Interests

Explore related searches

Contact this professor

Articles (10)

Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse

A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

CNS prophylaxis for diffuse large B-cell lymphoma

New Directions for Mantle Cell Lymphoma in 2022

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies

Collaborators (9)

Matthew Maurer

Chan Yoon Cheah

Graham McIlroy

Michael Buege

Stephen Opat

Matthew Ku

Eliza Hawkes

David Bond

Matthew Wilson

Make your next move.